medRxiv preprint doi: https://doi.org/10.1101/2023.03.28.23287745; this version posted March 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Efficacy and feasibility of Pharmacoscopy-guided 1 treatment for acute myeloid leukemia patients that 2 exhausted all registered therapeutic options. 3

4 ¹Jonas Andreas Schmid⁺, ²Yasmin Festl⁺, ²Yannik Severin⁺, ³Ulrike Bacher, ⁴Marie-Noëlle Kronig, ²Berend Snijder^{*§}, ⁴Thomas Pabst^{\$} 5

6	1	Faculty of Medicine University of Bern, Bern, Switzerland;
7	2	Department of Biology, Institute of Molecular Systems Biology, ETH Zürich, Zürich, Switzerland;
8	3	Department of Hematology; Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland;
9	4	Department of Medical Oncology; Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland;
10	+	Shared first authors
11	\$	Shared last authors;
12	*	Correspondence: Berend Snijder, Prof. Dr.; Assistant Professor; Department of Biology, Institute of Molecular Systems Biology,
13		ETH Zürich, 8093 Zürich, Switzerland; snijder@imsb.biol.ethz.ch, +41446337149
14		

15 B.S. was a scientific co-founder of Allcyte GmbH, which has been acquired by Exscientia. B.S. is a shareholder of Exscientia and a co-16 inventor on U.S. patent application 15/514,045 relevant to the study. B.S. declares research funding from Roche and speaker fees from 17 Novartis, GSK, and AbbVie. All other authors declare no potential conflicts of interest.

18 Abstract: Elderly or unfit patients with relapsed acute myeloid leukemia (AML) face a poor prognosis and are 19 likely to rapidly exhaust all registered treatment options. Pharmacoscopy, an image-based ex vivo drug screening 20 platform, has previously been suggested as a tool for treatment selection in AML. We used pharmacoscopy to 21 generate personalized treatment recommendations for 30 relapse settings of 24 AML patients which exhausted all 22 standard therapeutic options. We evaluated whether pharmacoscopy can be employed within the narrow 23 timeframe available under an AML relapse setting, how often recommended regimens could be started and 24 whether they provided durable clinical benefits. 17 of 30 screens (56.7%) resulted in patients receiving a 25 recommended therapy, leading to promising trends in clinical response and survival. A drug regimen's integrated 26 pharmacoscopy score proved to be an excellent predictor of clinical response: Patients receiving a regimen with 27 above-median scores showed significantly higher rates of complete remission (OR 3.01, p < 0.0005) and 28 significantly longer overall survival (ratio 3.39, p < 0.006). We conclude that pharmacoscopy is an efficient and 29 valuable tool for therapy selection in AML at relapse and propose concrete measures to further improve clinical 30 implementation.

Keywords: Acute myeloid leukemia (AML), DARTT-1, ex vivo drug screen, personalized treatment, elderly 31 32 patients, pharmacoscopy, functional precision medicine.

33 1. Introduction

34 Presently, the standard curative treatment strategy for acute myeloid leukemia (AML) is comprised of intensive 35 induction chemotherapy followed by consolidation treatment and allogeneic hematopoietic stem cell 36 transplantation¹. However, a significant amount of AML patients are unable to undergo such intensive treatment, 37 owing to their advanced age, comorbidities and/or poor performance status². These limitations are even more 38 pronounced in AML patients at relapse due to increased morbidity related to previous treatment attempts, leading 39 to a particularly poor prognosis. Only a few licensed and standardly reimbursed protocols are currently available 40 for AML patients at relapse unable to undergo intensive re-induction protocols and these tend to be quickly exhausted. The situation is aggravated by the rapidly progressive nature of AML at relapse which severely restricts 41 42 the timeframe to select an optimal therapy regimen³. Thus, there is a substantial unmet medical need in this patient 43 group.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.28.23287745; this version posted March 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

44 The rapid expansion of gene sequencing technology has allowed for the development of molecularly targeted therapy approaches both in newly diagnosed and relapsed AML (e.g., with FLT3 or IDH1/IDH2 mutations). 45 However, such strategies have provided modest clinical benefits and are only open to a relatively small subset of 46 47 patients at relapse^{4,5}. Hence, there currently is a lack of reliable means to select personalized treatment regimens 48 for AML patients at relapse, a challenge that also extends to other cancer entities⁶. Recent studies have 49 demonstrated the effectiveness of an image-based ex vivo drug screening platform called pharmacoscopy to 50 retrospectively predict the clinical treatment response in AML patients^{7,8}. Furthermore, pharmacoscopy has been 51 shown to provide valuable guidance when selecting targeted therapies in patients with a range of aggressive 52 hematological malignancies lacking standard treatment protocols9. Prior studies have tried to integrate ex vivo 53 drug screening approaches into the clinical management of AML^{7,9,10} but so far none has focused exclusively on 54 AML patients at relapse that had exhausted all standard therapeutic options, which pose an exceptional challenge 55 due to the severely restricted timeframe available for therapy selection at this stage. Furthermore, previous studies 56 have not addressed the issue of obtaining financial coverage for therapies selected in this way, an issue that is 57 inherent to all currently available drug screening approaches.

58 In this prospective, non-randomized, single-center observational study, we primarily aim to establish whether 59 pharmacoscopy can be successfully integrated into the clinical decision-making process when selecting individualized treatment protocols for AML patients at relapse that have exhausted all standard therapy options. 60 61 We evaluated whether the suggested therapies can be made available to the patients within a clinically tolerable 62 time frame and with adequate financial coverage. In addition, we assessed if pharmacoscopy-based therapy 63 recommendations can provide a measurable and lasting clinical benefit in our heavily pretreated and frail study 64 group.

65 2. Materials and Methods

In our prospective, non-randomized, single-center observational study (DARTT-1; NCT05732688; BASEC-ID: 66 67 2021-01294, Department of Medical Oncology, University Hospital Bern, Switzerland), we enrolled adult AML 68 patients at relapse who were unable to undergo intensive re-introduction treatments and had exhausted standard 69 treatment options. We excluded patients who had not yet undergone previous treatment attempts or still had other 70 treatment options available. We used an image-based ex vivo drug screening platform, called pharmacoscopy, to 71 generate personalized treatment recommendations for each patient based on samples of peripheral blood, bone 72 marrow, or skin/subcutaneous biopsies. The drug screens were performed at the laboratory of Prof. Berend 73 Snijder, Institute of Molecular Systems Biology, at the ETH Zurich. This group has recently developed and 74 validated a pioneering image-based ex vivo drug screening platform for patients with aggressive hematological 75 malignancies, called pharmacoscopy (Figure 1), and all screens were conducted as previously described ^{7–9}. The 76 results of the drug screen were communicated to the treating oncologist in the form of a short list of top-scoring 77 drugs recommended for the treatment of the respective patient, combined with reports on the screening results for 78 all tested compounds. If the recommended compounds could not be made available with adequate financial 79 coverage within a clinically reasonable time frame, the treating oncologist provided the patient with a therapy 80 regimen based on their medical history and previously established in-house guidelines at our department. If the 81 patient chose not to undergo further treatment, they were provided with best supportive care.

82 We enrolled 24 patients who were screened at least once, and an additional 5 patients were screened a second or 83 third time after relapsing. A total of 30 screening events with subsequent treatment and follow-up were included 84 in our intention to treat population (Figure 2). We obtained signed informed consent from all patients and the 85 study was carried out in accordance with good clinical practice and approved by relevant institutional review 86 boards and regulatory agencies. Screening instance and Patient IDs are not known to anyone besides the authors.

- 87 To assess response rates and outcome metrics, we monitored patients using clinical assessments, regular blood
- testing, and bone marrow aspirations during routine follow-up visits after the start of a newly chosen treatment. 88
- 89 We evaluated each screening instance as an individual event and calculated the blast reduction capacity (PCY
- 90 score, see more detail in supplementary) of a patient's given therapy regimen by summing up the PCY scores of

medRxiv preprint doi: https://doi.org/10.1101/2023.03.28.23287745; this version posted March 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

- 91 the individual compounds. Using this metric, we divided patients into two groups based on their therapy regimen's
- 92 ex vivo blast reduction capacity (above or below the median of the study population). The primary endpoints of
- 93 the study were the frequency of patients realizing a complete remission (CR) in the bone marrow, overall survival 94
- (OS), and event-free survival (EFS). We assessed these endpoints by comparing patients who received an 95
- officially recommended therapy versus those who received a therapy that had not been mentioned in the screening
- 96 report summary sent to the treating physician. Further details on enrollment, drug screening, statistical analyses
- 97 and data availability can be found in the extended methods.

98 3 Data availability statement

The data required to reproduce our results are included in the tables and supplementary tables. Additional data 99 100 generated in this study are not publicly available due to information that could compromise patient privacy or

101 consent but are available upon reasonable request from the corresponding author.

102 4. Results

103 4.1. Patient characteristics

104 24 patients were enrolled in the study and screened at least once. All patients were pre-treated with a median of 2 105 previous treatment lines (interquartile range 1-3) and had exhausted all standard therapeutic options for relapsed 106 AML, including all marker-based therapy options. Five out of 24 patients (20.8%) had undergone previous high-107 dose chemotherapy. The median age of the study population was 68.5 years (interquartile range 66-73) and the 108 gender distribution was 62.5% male vs 37.5% female. According to ELN risk category¹ 12.5% of the patients 109 were classified as favorable, 37.5% intermediate and 50.0% adverse. The median time from diagnosis to entry 110 into the study was 12.5 months with an interquartile range of 4.5-24.8 months. Demographics and the number of previous treatment lines for these 24 patients are listed in Table 1. A more detailed overview of the study 111 112 population can further be found in Supplementary Table S2, listing patient characteristics at the time of first 113 diagnosis.

114 In the following subsections, we divided our study population according to two stratification strategies. Namely, 115 by whether or not the patient received a therapy regimen recommended by the pharmacoscopy screen and by the 116 ex vivo blast reduction capacity of their chosen therapy regimen (i-PCY score of the chosen regimen). Neither of 117 the two patient stratification strategies differed significantly in their patient characteristics (see Supplementary 118 Table S3). However, when looking at the number of previous treatment lines, the difference between patients 119 receiving a recommended therapy and those that did not, borders on significance (p 0.0528), with the patients receiving a recommended therapy having a slightly higher median number of previous therapy lines (3 vs 2). In 120 121 addition to the first pharmacoscopy screen of each patient, five of the 24 patients were screened a second time 122 after a confirmed relapse or progression of the AML under their initially chosen treatment protocol. One of the 123 doubly screened patients was screened a third time after a further relapse, resulting in a total of 30 separate screening events with subsequent therapy choices and clinical follow-up. These 30 screening instances constitute 124 125 our intention to treat population. Of note, one of the patients presented with a subcutaneous relapse of a bi-specific 126 AML (patient ID 11) for which we screened a skin biopsy, and confirmed the absence of toxicity of the 127 recommended treatments based on an additional screen on a matched bone marrow biopsy that was confirmed 128 AML negative by clinic diagnostics (Supplementary Figure S1). See Supplementary Table S1 for details on 129 each test, including markers used per patient and the pharmacoscopy results for each of the 30 screening instances. All screens were performed during the period between April, 1st 2021 and June, 30th, 2022. For the following 130 131 statistical analyses, each screening event will be treated as a separate data point.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.28.23287745; this version posted March 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

133 4.2. Screening results and treatment choice

Table 2 lists a summary of the ex vivo drug screening results, waiting times, characteristics of treatment choice 134 135 and duration of therapy administration. The median waiting time for the screening results was 5.0 days (interquartile range 4.0-6.0). A median of 5.5 drugs per patient (interquartile range 4.3-8.8), ranked by their 136 137 predicted efficacy for the respective patient, were mentioned as official recommendations in the reports sent to 138 the treating physicians. Reports also regularly contained suggestions for potential combinations of the 139 recommended compounds based on the results for the individual components. In 17 (56.7%) instances the drug 140 screen resulted in the patient receiving at least one of the recommended therapy options (either a single drug or a 141 combination, depending on the recommendations of the screen), while no recommended drug was administered 142 in 13 (43.3%) instances. Of these 13 instances, 9 (30.0% of all screening instances) resulted in patients receiving 143 an AML-specific therapy not explicitly recommended by the screen. Four patients did not start another AML-144 specific therapy due to their rapidly deteriorating condition or refusal of further therapy attempts and were 145 therefore switched to best supportive care (see Figure 2). The duration from receiving the drug recommendations 146 to the start of a new therapy regimen was a median of 11 days (IQR 6-24). The median duration of therapy 147 administration was 65.5 days (IQR 26.5-183.8) for all patients receiving an AML specific therapy (recommended 148 and non-recommended). When looking only at patients receiving a regimen recommended by the screen, the 149 median duration of therapy administration was 69.0 days (IQR 21.0-171.0) versus 47.0 days (40.0-214.0) for 150 patients receiving a non-recommended therapy. Out of the 166 single compounds or combinations of compounds in the library used for the ex vivo drug screen 59 were recommended (as single compounds and/or in specific 151 152 combination regimens) at least once in the screening reports (pharmacoscopy reports) sent to the treating 153 oncologist. Out of these, 17 compounds were recommended five times or more. Table 3 lists the top six most 154 recommended drugs, which were the BCL-2 Inhibitors navitoclax and venetoclax, the alkaloid omacetaxine 155 (formerly named homoharringtonine), the purine analogue cladribine, the proteasome inhibitor carfilzomib and the HDAC-Inhibitor panobinostat. Despite having been among the most frequently recommended drugs, both 156 omacetaxine and panobinostat were never administered to patients in the study due to the difficulty of obtaining 157 158 financial coverage for their use in AML therapy. Eight individual compounds that had been recommended in a 159 screening report were administered at least once to the respective patient. These include venetoclax, cladribine, 160 cytarabine, azacytidine, navitoclax, carfilzomib, bortezomib and pomalidomide. All the recommended and 161 administered drugs can also be found in the bar plots in **Supplementary Figure S2**.

162 4.3. Response

163 During the study period the overall response to the chosen therapy regimen in the bone marrow could be assessed 164 in 25 screening instances. The results of this analysis are depicted in **Table 4** and **Supplementary Figure S3**. We 165 found that a significantly higher percentage (45.5% vs 21.4%) of patients receiving a drug combination with an 166 above-median ex vivo blast reduction capacity (i-PCY score of the chosen regimen) achieved a CR than patients receiving a regimen with a low blast reduction capacity (i-PCY score of the chosen regimen below the median) 167 (OR 3.078, p 0.0005). Conversely, patients that achieved a complete remission tended to receive treatment 168 regimens with a higher ex vivo blast reduction capacity (mean i-PCY score 0.278) than patients that did not achieve 169 170 a CR (mean i-PCY score 0.155) (Supplementary Figure S4 and Supplementary Table S4). When comparing 171 patients receiving a recommended therapy with patients receiving a regimen that had not been officially 172 recommended the difference in the relative number of complete responders is also present albeit less pronounced 173 (35.3% vs 25.0%, OR 1.615, p 0.1646).

174 *4.4 Outcome*

175 The durability of response to the chosen treatment was evaluated by two different outcome measures consisting

of event-free survival (EFS) and overall survival (OS) as defined by standard outcome definitions in AML¹.

177 Looking at these two outcome measures we found that patients receiving a recommended therapy had a median

- 178 OS of 18.0 weeks versus 8.0 weeks in the patients not receiving a recommended therapy (ratio 2.250, 95% CI of
- 179 ratio 1.021 to 4.958) (Figure 3a). Median EFS was 11.1 weeks in patients receiving a recommended therapy
- 180 compared to 6.3 weeks in the group not receiving a recommended regimen (ratio 1.773, 95% CI of ratio 0.805 to

medRxiv preprint doi: https://doi.org/10.1101/2023.03.28.23287745; this version posted March 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license.

181 3.906) (Figure 3b). When stratifying the intention to treat population by the ex vivo blast reduction capacity of their therapy regimen (i-PCY score of the individual regimens) we found that patients receiving a regimen with a 182 blast reduction capacity above the median of the study population showed a median OS of 28.6 weeks as opposed 183 184 to 8.4 weeks in patients receiving a regimen with low ex vivo blast reduction capacity (i-PCY score below the 185 median) (ratio 3.390, 95% CI of ratio 1.506 to 7.632, p 0.006) (Figure 3c). Median EFS for patients receiving a 186 regimen with a blast reduction capacity above the median was 12.4 in comparison to 6.4 weeks for the patients 187 treated with a regimen that had a blast reduction capacity below the median (ratio 1.933, 95% CI of ratio 0.859 to 188 4.353, p 0.0446) (Figure 3d). Stratifying only the patients that received an AML-specific therapy by the ex vivo 189 blast reduction capacity of their treatment regimen, we found that regimens with an above-median blast reduction 190 capacity led to a median OS of 28.6 weeks versus 11.0 weeks in patients with a treatment regimen scoring below 191 the median (ratio 2.597, 95% CI of ratio 1.062 to 6.354, p 0.0167) (Figure 3e). Looking at EFS for the same 192 subgroups we found a median EFS of 12.4 weeks in patients receiving a regimen with an ex vivo blast reduction 193 capacity above the median in comparison to 8.1 weeks in patients with a regimen that had a blast reduction 194 capacity below the median (ratio 1.540, 95% CI of ratio 0.629 to 3.767) (Figure 3f).

195 5. Discussion

196 Despite the expansion of targeted therapies for AML patients, as well as other approaches such as post-transplant 197 maintenance therapy, relapse of AML remains the main cause of mortality in patients with this entity. The

198 exceptionally poor prognosis in this patient group is aggravated further by the very limited availability of

199 registered therapy options at this stage and the rapidly progressive nature of their disease³. Thus, improving the

200 prognosis of patients at relapse of AML that have exhausted all registered therapy options remains a critical

201 unsolved issue.

202 We here evaluated a novel approach, basing treatment decisions in this patient group on a selection of treatments

203 following the recommendations of pharmacoscopy, an automated imaging-based ex vivo drug screening platform.

204 Using this platform, we tested chemo-, targeted, and immunotherapeutic drugs for their capacity to selectively

205 eradicate leukemic blasts in patient derived peripheral blood, bone marrow samples or skin/subcutaneous biopsies.

206 In this prospective, non-randomized, single-center observational study, we could demonstrate that the integration

207 of pharmacoscopy into the clinical decision-making for the treatment of AML patients at relapse is technically

208 feasible within the narrow timeframe available and proofs beneficial to the patients.

209 Patients do not have to undergo strenuous diagnostic tests, as all the material required for the screen can be gained 210 from routine bone marrow punctures, blood draws or skin/subcutaneous biopsies performed during clinical 211 follow-up visits with their treating oncologist. We found that the screening procedure is fast, taking a median of 212 only 5 days to deliver the necessary results and new therapy protocols could be administered within a median of 213 11 days after receiving the pharmacoscopy results. Thus the procedure does not significantly slow down clinical

214 decision-making, which is a key concern in a rapidly progressing disease such as AML at relapse^{1,3}.

215 In our study cohort, a majority of the intention-to-treat population (56.7%) received a therapy regimen guided by 216 the screening results (either a single drug or a combination, depending on the recommendations of the screen). 217 Patients receiving a regimen recommended by the screen had a median duration of therapy administration of 69.0 218 days (IQR 21.0-171.0) compared to only 47.0 days (40.0-214.0) for patients receiving a non-recommended 219 therapy. This shows that pharmacoscopy helps direct the choice of therapy regimen and that comprehensive 220 financial coverage could be obtained for the majority of treatment plans derived in this way. Treatments based on 221 official recommendations from the screen appear to be effective, as the rate of CR is higher in patients receiving 222 a recommended therapy, 35.3% versus 25.0% in patients receiving a non-recommended therapy, leading to an 223 odds ratio of 1.615 for a complete remission. This difference in response appears durable with patients receiving 224 a recommended therapy having a 2.3 fold longer OS (95% CI 1.021 to 4.958) and 1.8 fold longer EFS (95% CI 225 0.805 to 3.906) than those not receiving a recommended regimen. However, we found that the ex vivo blast 226 reduction capacity (i-PCY score of a patient's treatment regimen) is a better ex-post predictor of response and 227 overall outcome than whether the chosen treatment is based on the median 5.5 compounds listed as recommended medRxiv preprint doi: https://doi.org/10.1101/2023.03.28.23287745; this version posted March 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

228 in the pharmacoscopy reports sent to the treating physician. We found that patients receiving a therapy regimen 229 with an ex vivo blast reduction capacity above the median of the study population showed significantly higher 230 relative rates of complete remission in the bone marrow than those receiving a regimen with a blast reduction 231 capacity below that median (OR 3.078, p fisher test 0.0005). Patients receiving regimens with a high ex vivo blast 232 reduction capacity (above the population median) also showed significantly longer OS (28.6 weeks vs 8.4 weeks) 233 and EFS (12.4 weeks vs 6.4 weeks). The significant effect of the ex vivo blast reduction capacity in a treatment 234 regimen on OS was even present when only looking at patients receiving an AML-specific therapy. Thus, a key 235 takeaway from our study is that when using pharmacoscopy for clinical decision-making, oncologists should base 236 their choice of treatment regimen on the i-PCY score of the respective regimen rather than relying only on the 237 shortlist of recommended compounds. A further finding that strengthens this point is that only a relatively small 238 number of different compounds used in the ex vivo drug screen were included in the final treatment regiments of 239 the individual patients. Only eight compounds out of 166 in the screening library were administered to patients at 240 least once after having officially been recommended in the screening reports. These prominently include 241 compounds that have already been established in the treatment of AML such as azacvtidine and the BCL-2 242 inhibitor venetoclax¹² or cladribine and cytarabine¹³. This skew towards more established treatment regimens is 243 probably owed to their better availability, with health insurance companies being more open to providing financial 244 coverage for more conventional therapy plans. This is an inherent challenge for any drug screening approach using 245 large libraries, since it is not feasible to establish financial coverage for all substances and for every single patient before the actual screens have been run. We, therefore, suggest that future screening reports from pharmacoscopy 246 247 should always highlight a performance measure of drugs commonly used in the treatment of AML patients. This 248 would allow the treating oncologist to prioritize between readily available standard therapy options even when 249 the highest scoring compounds indicated by the drug screen prove unavailable within a reasonable time frame.

250 Our study also highlights a number of drugs that have so far not been introduced into standard treatment protocols 251 for AML at relapse but might be promising therapeutic options in the future. The most frequently recommended 252 drug in our screen was the BCL-2 inhibitor navitoclax, a compound that is currently employed in early phase 253 clinical studies for the treatment of solid tumours as well as acute lymphocytic leukemia¹⁴. The protein translation 254 inhibitor omacetaxine was the third most frequently recommended drug in our screen (behind navitoclax and 255 venetoclax). Omacetaxine has been approved for the treatment of chronic myelogenous leukemia¹⁵ and has shown 256 promising results in pre-clinical studies on AML treatment¹⁶. Other frequently recommended drugs include carfilzomib, a drug standardly used in the treatment of multiple myeloma¹⁷, as well as the HDAC-inhibitor 257 258 panobinostat which has shown mixed results in both preclinical and early phase clinical studies on AML 259 treatment¹⁸.

260 Previous studies have tried to integrate ex vivo drug screening into the process of therapy selection in AML patients^{9,10}. Malani et al.¹⁰ reported that 17 out of 29 (58.6%) treated AML patients in their study achieved a PR 261 262 or better. And, in Kornauth et al.⁹, 6 out of the 14 (42.8%) treated AML patients achieved a PR or better. In 263 comparison with our results, with 8 out of 17 (47.1%) AML patients achieving a PR or better, these prior findings 264 are on par with our results. However, direct comparisons are complicated, as both previous studies included some 265 patients for whom more standard treatment options were available, and considered molecular profiling in parallel 266 to the drug response profiling. In contrast, our patients were all unfit to undergo intensive re-introduction 267 treatments with subsequent hematopoietic stem cell transplantation and had exhausted all available standard 268 treatment protocols, meaning marker-based therapy options were no longer open to our patient cohort. Hence, in contrast to Kornauth et al.⁹ and Malani et al.¹⁰, we had to rely solely on *ex vivo* drug screening results for therapy 269 270 selection, making the observed 47.1% PR+CR rate an encouraging signal. Furthermore, in contrast to Malani et 271 al.¹⁰, we provide a control group consisting of patients for whom a pharmacoscopy guided therapy protocol could 272 not be obtained. And we go beyond these previous studies by addressing the problem of obtaining cost coverage 273 for AML therapy protocols selected on the basis of ex vivo drug screens, which is a key issue in the clinical setting.

A major limitation of our study is the lack of randomization of patients into different treatment groups. This flaw is inherent to our study design where it cannot be known whether recommended treatments would prove available for the patient before the screen has been run. However, the significant stratification of the intention-to-treat population by the *ex vivo* blast reduction capacity of their treatment regimen (i-PCY score of the chosen regimen) medRxiv preprint doi: https://doi.org/10.1101/2023.03.28.23287745; this version posted March 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

- 278 suggests an efficient design for future randomized trials. Patients could be randomized into an intervention group,
- 279 which would receive a treatment regimen optimized by the ex vivo blast reduction capacity, and into a control
- 280 group, which would be treated with a regimen according to the physicians choice or in house guidelines.

281 In conclusion, we can state that pharmacoscopy can rapidly provide valuable decision-making cues for physicians

282 when trying to choose the optimal therapy for AML patients at relapse. The ex vivo blast reduction capacity

- 283 (indicated by a therapy regimens i-PCY score) is a metric that is simple to interpret with the i-PCY score being a
- 284 numerical value resembling standard laboratory results that physicians interpret on a daily basis. It can readily be
- 285 used as an indicator to choose between already established treatment protocols or to design novel therapy plans
- 286 for patients that would otherwise have few suitable treatment options. We suggest that image-based ex vivo drug
- 287 screening may standardly be employed in AML patients at relapse to provide them with optimized treatment plans 288 and further refine the metrics on which physicians base their choice of therapy regimens.

289 Contributions

290 JAS recorded clinical response, carried out statistical analysis, assisted in the enrolment of the patients and wrote 291 the initial draft of the manuscript. YF & YS performed all pharmacoscopy experiments and the associated 292 computational analysis, helped write the final manuscript, and, together with BS, provided treatment 293 recommendations. MNK recruited and enrolled the patients. UB Assisted in conceptualizing the study and writing 294 of the manuscript. BS & TB conceived, supervised, and funded the study, advised on experimental design, data 295 interpretation and helped writing the manuscript. All authors read and approved the final version of the 296 manuscript.

297 References

- 298 1. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN 299 recommendations from an international expert panel. Blood. 2017;129(4):424-447. doi:10.1182/blood-300 2016-08-733196
- 2. 301 Laribi K, Sobh M, Ghez D, Baugier de Materre A. Impact of age, functional status, and comorbidities on 302 quality of life and outcomes in elderly patients with AML: review. Ann Hematol. 2021;100(6):1359-1376. 303 doi:10.1007/s00277-020-04375-x
- Webster JA, Luznik L, Gojo I. Treatment of AML Relapse After Allo-HCT. Front Oncol. 304 3. 305 2021;11(December):1-16. doi:10.3389/fonc.2021.812207
- 4. 306 Megías-Vericat JE, Ballesta-López O, Barragán E, Martínez-Cuadrón D, Montesinos P. Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control? Blood Rev. 307 2020;44(March):100675. doi:10.1016/j.blre.2020.100675 308
- 309 5. Ma J, Ge Z. Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia. Bosn J Basic Med Sci. 2021;21(4):409-421. doi:10.17305/bjbms.2020.5485 310
- 311 6. Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat Med. 312 2017;23(9):1028-1035. doi:10.1038/nm.4389
- 7. 313 Snijder B, Vladimer GI, Krall N, et al. Image-based ex-vivo drug screening for patients with aggressive 314 haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol. 315 2017;4(12):e595-e606. doi:10.1016/S2352-3026(17)30208-9
- 316 8. Heinemann T, Kornauth C, Severin Y, et al. Deep Morphology Learning Enhances Ex Vivo Drug 317 Profiling-Based Precision Medicine . Blood Cancer Discov. 2022;3(6):502-515. doi:10.1158/2643-3230.bcd-21-0219 318
- 319 9. Kornauth C, Pemovska T, Vladimer GI, et al. Functional Precision Medicine Provides Clinical Benefit in

medRxiv preprint doi: https://doi.org/10.1101/2023.03.28.23287745; this version posted March 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

- 320 Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discov. 2022;12(2):372-387. doi:10.1158/2159-8290.CD-21-0538 321
- 322 10. Malani D, Kumar A, Brück O, et al. Implementing a Functional Precision Medicine Tumor Board for 323 Acute Myeloid Leukemia. Cancer Discov. 2022;12(2):388-401. doi:10.1158/2159-8290.CD-21-0410
- 324 11. Severin Y, Hale BD, Mena J, Goslings D, Frey BM, Snijder B. Multiplexed high-throughput immune cell 325 imaging reveals molecular health-associated phenotypes. Sci Adv. 2022;8(44):eabn5631. 326 doi:10.1126/sciadv.abn5631
- 327 12. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute 328 Myeloid Leukemia. N Engl J Med. 2020;383(7):617-629. doi:10.1056/nejmoa2012971
- 329 13. Budziszewska BK, Salomon-Perzyński A, Pruszczyk K, et al. Cladribine combined with low-dose 330 cytarabine as frontline treatment for unfit elderly acute myeloid leukemia patients: Results from a 331 prospective multicenter study of polish adult leukemia group (palg). Cancers (Basel). 2021;13(16). 332 doi:10.3390/cancers13164189
- 14. 333 Mohamad Anuar NN, Nor Hisam NS, Liew SL, Ugusman A. Clinical Review: Navitoclax as a Pro-334 Front Pharmacol. Apoptotic and Anti-Fibrotic Agent. 2020;11(November):1-16. 335 doi:10.3389/fphar.2020.564108
- 336 15. Gandhi V, Plunkett W, Cortes JE. Omacetaxine: A protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014;20(7):1735-1740. doi:10.1158/1078-0432.CCR-13-1283 337
- Mill CP, Fiskus W, DiNardo CD, et al. Effective therapy for AML with RUNX1 mutation by cotreatment 338 16. 339 translation and BCL2. Blood. 2022;139(6):907-921. with inhibitors of protein 340 doi:10.1182/blood.2021013156
- 17. Muchtar E, Gertz MA, Magen H. A practical review on carfilzomib in multiple myeloma. Eur J Haematol. 341 2016;96(6):564-577. doi:10.1111/ejh.12749 342
- 343 18. José-Enériz ES, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid leukemia. 344 Cancers (Basel). 2019;11(11):1-24. doi:10.3390/cancers11111794



Figure 1. Pharmacoscopy workflow for AML at relapse: Patient samples (bone marrow draws. peripheral blood, or subcutaneous/skin samples) were shipped by courier to the pharmacoscopy lab. There, the cells from the samples were processed by either density centrifugation (blood and bone marrow) or tissue dissociation (skin) and seeded into 384-well imaging plates, with each well containing a chemo- or immunotherapeutic compound from our test library. The plates were then incubated overnight. Immunofluorescence stainings against specific surface antigen characteristics of the patient's leukemic cells were used to distinguish between healthy cells and malignant blasts. The cells were then subjected to automated confocal microscopy (Opera Phenix, Perkin Elmer) and image analysis using nuclear morphology to quantify the death of malignant and healthy cells, respectively. Based on this readout, the ex-vivo blast reduction capacity (PCY score) was calculated for each compound. Pharmacoscopy reports were provided to the treating oncologists in the form of a short list of topscoring drugs ranked by their predicted efficacy, as well as complete drug response profiles. The selection of treatment regimens was subsequently based on the pharmacoscopy report and the availability of compounds listed therein. If none of the listed compounds could be made available within a reasonable time frame, therapy regimens were chosen based on previously established inhouse guidelines at our department.



Figure 2. Trial profile: Diagram of study patients. * Patients were switched to best supportive care either because they refused further treatment, or due to their rapidly deteriorating health prohibiting additional AML-specific therapy attempts.



Figure 3. Outcome: a. Kaplan-Meier estimates of overall survival in the intention to treat population stratified by whether patients received an officially recommended therapy regimen (17 screening instances) or not (13 screening instances). **b.** Kaplan-Meier estimates of event free survival in the intention to treat population stratified by whether patients received an officially recommended therapy regimen or not (17 vs 13 screening instances). **c.** Kaplan-Meier estimates of overall survival in the intention to treat population stratified by the ex-vivo blast reduction capacity of their respective treatment regimen (i-PCY score) (14 screening instances above median i-PCY score and 16 bellow). **d.** Kaplan-Meier estimates of overall survival in the intention to treat population stratified by the ex-vivo blast reduction stratified by the ex-vivo blast reduction capacity of their respective treatment regimen (14 vs 16 screening instances). **e.** Kaplan-Meier estimates of overall survival in patients receiving an AML specific therapy stratified by the ex-vivo blast reduction capacity of their respective treatment regimen (12 screening instances s above median i-PCY score and 14 bellow). **f.** Kaplan-Meier estimates of event free survival in patients receiving an AML specific therapy stratified by the ex-vivo blast reduction capacity of their respective treatment regimen (12 screening instances s above median i-PCY score and 14 bellow). **f.** Kaplan-Meier estimates of event free survival in patients receiving an AML specific therapy stratified by the ex-vivo blast reduction capacity of their respective treatment regimen (12 screening instances). All P values calculated by Gehan-Breslow-Wilcoxon Test.

Age at start of the study (years) Median (IQR)	68.5 (66-73)
Sex (No. and share of Patients) Female Male	9.0 (37.5%) 15.0 (62.5%)
ELN Risk Category (No. and share of Patients) favorable intermediate adverse	3.0 (12.5%) 9.0 (37.5%) 12.0 (50.0%)
Time from diagnosis to study (months) Median (IQR)	12.5 (4.5-24.8)
Number of previous therapy lines Median (IQR)	2.0 (1.0-3.0)
No. and Share of patients with previous high dose chemotherapy	5.0 (20.8%)
Table 1: Summary of study group IQR: Interquartile range. No.: Number	

Waiting time for results, days Median (IQR)	5.0 (4.0-6.0)
No. of recommended compounds per patient Median (IQR)	5.5 (4.3-8.8)
Therapy choice per patient (No. of patients and share of intention to treat population)	
Recommendation received	17.0 (56.7%)
Recommendation not received	13.0 (43.3%)
AML specific therapy	9.0 (30.0%)
Best supportive care	4.0 (13.3%)
Duration from recommendation to administration of therapy (days)	
Median (IQR)	11.0 (6.0-24.0)
Duration of therapy administration (days, all patients)	
Median (IQR)	65.5 (26.5-183.8)
Duration of therapy administration (days, recommended therapy) Median (IQR)	69.0 (21.0-171.0)
Duration of therapy administration (days, other AML specific therapy) Median (IQR)	47.0 (40.0-214.0)
No. of compounds recommended at least once	59.0
No. of compounds recommended 5 times or more	17.0
No. of recommended compounds administered to patients at least once	8.0

Table 2: Overview of *ex vivo* drug screen and treatment choice

IQR: Interquartile range, No.: Numbers

Compound	Times recommended	Times administered		
1. Navitoclax	14	1		
2. Venetoclax	13	11		
3. Omacetaxine	12	0		
4. Cladribine	10	6		
5. Carfilzomib	9	1		
6. Panobinostat	9	0		

Table 3: Most frequently recommended drugs

The table lists the 6 most frequently recommended drugs in the screening reports during our study. Despite their frequent recommendation, some of these drugs were never administered to patients due to difficulties in obtaining financial coverage for their use in the treatment of AML patients.

Subgroup	No. of screening instances with a known response in the bone marrow (n=25)	Response			
		CR	PR	SD	R
Treatment recommended	17	6 (35.3%)	2 (11.8%)	2 (11.8%)	7 (41.2%)
Treatment not recommended	8	2 (25.0%)	0 (0.0%)	1 (12.5%)	5 (62.5%)
i-PCY score of regimen > median	11	5 (45.5%)	1 (9.1%)	2 (18.2%)	3 (27.3%)
i-PCY score of regimen < median	14	3 (21.4%)	1 (7.1%)	1 (7.1%)	9 (64.3%)

Table 4: Overall response by subgroupsCR: Complete remission, PR: Partial remission, SD: Stable disease, R: Refractory, No.: Number